Literature DB >> 9159157

Keratinocyte expression of the type 2 interleukin 1 receptor mediates local and specific inhibition of interleukin 1-mediated inflammation.

T Rauschmayr1, R W Groves, T S Kupper.   

Abstract

Epidermal keratinocytes can express two types of interleukin 1 (IL-1) receptors: IL-1R1, which is active in signal transduction, and the less well characterized IL-1R2, which is incapable of transducing a signal and can be shed from cells. The binding of IL-1 in solution by IL-1R2 has been demonstrated, and it has been proposed to inhibit IL-1-mediated responses through this mechanism. We and others have reported that keratinocytes can be induced to express IL-1R2 both in vitro and in vivo, often under conditions that also favor IL-1 gene expression. We hypothesized that production of IL-1R2 by keratinocytes would be an efficient means to achieve local inhibition of IL-1-mediated responses without systemic consequences. To test this hypothesis, we have generated transgenic mice that constitutively express IL-1R2 on basal keratinocytes. Keratinocytes cultured from these animals shed the soluble form of the receptor into culture supernatants, and IL-1-inducible production of granulocyte/macrophage colony-stimulating factor was markedly inhibited. In vivo, acute cutaneous vascular leakage, as well as chronic inflammation induced by a well characterized IL-1-dependent stimulus, was significantly inhibited in IL-1R2 transgenic animals. In contrast, contact hypersensitivity was unaffected, suggesting that overexpression of IL-1R2 did not inhibit all types of inflammation globally. Finally, systemic injection of IL-1 induced equivalent levels of plasma IL-6 in IL-1R2 transgenic and nontransgenic mice, suggesting that the activity of the transgenic IL-1R2 remained predominantly local and did not influence systemic IL-1 responses. We conclude that tissue-specific production of IL-1R2 can mediate IL-1 antagonism in tissue microenvironments without systemic consequences. Our transgenic mice may be a useful tool for determining the degree to which different types of cutaneous inflammation depend on the IL-1 system.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9159157      PMCID: PMC20863          DOI: 10.1073/pnas.94.11.5814

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  36 in total

1.  cDNA cloning of an intracellular form of the human interleukin 1 receptor antagonist associated with epithelium.

Authors:  S Haskill; G Martin; L Van Le; J Morris; A Peace; C F Bigler; G J Jaffe; C Hammerberg; S A Sporn; S Fong
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-01       Impact factor: 11.205

2.  In vivo cytokine expression in normal and perturbed murine skin--analysis by competitive quantitative polymerase chain reaction.

Authors:  O Kilgus; E Payer; S Schreiber; A Elbe; R Strohal; G Stingl
Journal:  J Invest Dermatol       Date:  1993-05       Impact factor: 8.551

3.  Interleukin 1 signaling occurs exclusively via the type I receptor.

Authors:  J E Sims; M A Gayle; J L Slack; M R Alderson; T A Bird; J G Giri; F Colotta; F Re; A Mantovani; K Shanebeck
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

4.  Interleukin-1 receptor antagonist in normal and psoriatic epidermis.

Authors:  C Hammerberg; W P Arend; G J Fisher; L S Chan; A E Berger; J S Haskill; J J Voorhees; K D Cooper
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

5.  Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4.

Authors:  F Colotta; F Re; M Muzio; R Bertini; N Polentarutti; M Sironi; J G Giri; S K Dower; J E Sims; A Mantovani
Journal:  Science       Date:  1993-07-23       Impact factor: 47.728

6.  Modulation of interleukin-1 alpha mRNA expression in mouse epidermis by tumor promoters and antagonists.

Authors:  W Y Lee; S M Fischer; A P Butler; M F Locniskar
Journal:  Mol Carcinog       Date:  1993       Impact factor: 4.784

7.  An essential role for Langerhans cell-derived IL-1 beta in the initiation of primary immune responses in skin.

Authors:  A H Enk; V L Angeloni; M C Udey; S I Katz
Journal:  J Immunol       Date:  1993-05-01       Impact factor: 5.422

8.  Independent binding of interleukin-1 alpha and interleukin-1 beta to type I and type II interleukin-1 receptors.

Authors:  J Slack; C J McMahan; S Waugh; K Schooley; M K Spriggs; J E Sims; S K Dower
Journal:  J Biol Chem       Date:  1993-02-05       Impact factor: 5.157

9.  HepG2 cells predominantly express the type II interleukin 1 receptor (biochemical and molecular characterization of the IL-1 receptor).

Authors:  J G Giri; R Robb; W L Wong; R Horuk
Journal:  Cytokine       Date:  1992-01       Impact factor: 3.861

10.  Human keratinocytes produce but do not process pro-interleukin-1 (IL-1) beta. Different strategies of IL-1 production and processing in monocytes and keratinocytes.

Authors:  H Mizutani; R Black; T S Kupper
Journal:  J Clin Invest       Date:  1991-03       Impact factor: 14.808

View more
  27 in total

1.  Characterization of Spleen Transcriptome of Schizothorax prenanti during Aeromonas hydrophila Infection.

Authors:  Hua Ye; Shijun Xiao; Xiaoqing Wang; Zhiyong Wang; Zhengshi Zhang; Chengke Zhu; Bingjie Hu; Changhuan Lv; Shuming Zheng; Hui Luo
Journal:  Mar Biotechnol (NY)       Date:  2018-03-08       Impact factor: 3.619

2.  Interleukin-1 Receptor Type 2 Acts with c-Fos to Enhance the Expression of Interleukin-6 and Vascular Endothelial Growth Factor A in Colon Cancer Cells and Induce Angiogenesis.

Authors:  Ai-Chung Mar; Chun-Ho Chu; Hui-Ju Lee; Chia-Wen Chien; Jing-Jy Cheng; Shung-Haur Yang; Jeng-Kai Jiang; Te-Chang Lee
Journal:  J Biol Chem       Date:  2015-07-24       Impact factor: 5.157

3.  Budesonide epimer R or dexamethasone selectively inhibit platelet-activating factor-induced or interleukin 1beta-induced DNA binding activity of cis-acting transcription factors and cyclooxygenase-2 gene expression in human epidermal keratinocytes.

Authors:  W J Lukiw; R P Pelaez; J Martinez; N G Bazan
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-31       Impact factor: 11.205

4.  Integrative predictive model of coronary artery calcification in atherosclerosis.

Authors:  Michael McGeachie; Rachel L Badovinac Ramoni; Josyf C Mychaleckyj; Karen L Furie; Jonathan M Dreyfuss; Yongmei Liu; David Herrington; Xiuqing Guo; João A Lima; Wendy Post; Jerome I Rotter; Stephen Rich; Michèle Sale; Marco F Ramoni
Journal:  Circulation       Date:  2009-12-15       Impact factor: 29.690

5.  Human colon carcinomas constitutively express and shed type II IL-1 receptor, an IL-1 antagonist.

Authors:  Andrew W Stadnyk; Moorix M W Yeung; Sen Rong Yan
Journal:  Dig Dis Sci       Date:  2003-09       Impact factor: 3.199

6.  Overexpression of IL-1alpha in skin differentially modulates the immune response to scarification with vaccinia virus.

Authors:  Tian Tian; Luzheng Liu; Eva-Jasmin Freyschmidt; George F Murphy; Thomas S Kupper; Robert C Fuhlbrigge
Journal:  J Invest Dermatol       Date:  2008-07-10       Impact factor: 8.551

7.  UVB radiation generates sunburn pain and affects skin by activating epidermal TRPV4 ion channels and triggering endothelin-1 signaling.

Authors:  Carlene Moore; Ferda Cevikbas; H Amalia Pasolli; Yong Chen; Wei Kong; Cordula Kempkes; Puja Parekh; Suk Hee Lee; Nelly-Ange Kontchou; Iwei Yeh; Iwei Ye; Nan Marie Jokerst; Elaine Fuchs; Martin Steinhoff; Wolfgang B Liedtke
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-08       Impact factor: 11.205

Review 8.  Of Inflammasomes and Alarmins: IL-1β and IL-1α in Kidney Disease.

Authors:  Hans-Joachim Anders
Journal:  J Am Soc Nephrol       Date:  2016-08-11       Impact factor: 10.121

Review 9.  Regulation of IL-1 signaling by the decoy receptor IL-1R2.

Authors:  Thomas Schlüter; Carsten Schelmbauer; Khalad Karram; Ilgiz A Mufazalov
Journal:  J Mol Med (Berl)       Date:  2018-08-15       Impact factor: 4.599

Review 10.  Dual functionality of interleukin-1 family cytokines: implications for anti-interleukin-1 therapy.

Authors:  N M Luheshi; N J Rothwell; D Brough
Journal:  Br J Pharmacol       Date:  2009-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.